Agios Pharmaceuticals (AGIO) Stock Forecast, Price Target & Predictions
AGIO Stock Forecast
Agios Pharmaceuticals stock forecast is as follows: an average price target of $53.50 (represents a 51.04% upside from AGIO’s last price of $35.42) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
AGIO Price Target
The average price target for Agios Pharmaceuticals (AGIO) is $53.50 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $56.00 to $51.00. This represents a potential 51.04% upside from AGIO's last price of $35.42.
AGIO Analyst Ratings
According to 7 Wall Street analysts, Agios Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AGIO stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Agios Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Danielle Brill | Raymond James | $51.00 | $44.43 | 14.79% | 43.99% |
| Sep 27, 2024 | Andrew Berens | Leerink Partners | $56.00 | $45.61 | 22.78% | 58.10% |
| Sep 10, 2024 | Chris Raymond | Raymond James | $56.00 | $44.05 | 27.13% | 58.10% |
| Jun 17, 2024 | Chris Raymond | Raymond James | $55.00 | $43.42 | 26.67% | 55.28% |
| Jun 03, 2024 | Gregory Renza | RBC Capital | $53.00 | $44.26 | 19.75% | 49.63% |
| May 28, 2024 | Chris Raymond | Raymond James | $45.00 | $38.39 | 17.22% | 27.05% |
| Feb 03, 2023 | Piper Sandler | $41.00 | $30.18 | 35.85% | 15.75% | |
| Dec 01, 2022 | J.P. Morgan | $33.00 | $29.46 | 12.02% | -6.83% | |
| Nov 17, 2022 | Goldman Sachs | $32.00 | $27.13 | 17.95% | -9.66% | |
| Apr 30, 2021 | Peter Lawson | Barclays | $70.00 | $55.80 | 25.45% | 97.63% |
The latest Agios Pharmaceuticals stock forecast, released on Oct 31, 2024 by Danielle Brill from Raymond James, set a price target of $51.00, which represents a 14.79% increase from the stock price at the time of the forecast ($44.43), and a 43.99% increase from AGIO last price ($35.42).
Agios Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 6 |
| Avg Price Target | - | $53.50 | $52.67 |
| Last Closing Price | $35.42 | $35.42 | $35.42 |
| Upside/Downside | -100.00% | 51.04% | 48.70% |
In the current month, the average price target of Agios Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Agios Pharmaceuticals's last price of $35.42. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | Raymond James | Outperform | Outperform | Hold |
| Oct 10, 2024 | RBC Capital | Market Perform | Market Perform | Hold |
| Sep 27, 2024 | Leerink Partners | Market Perform | Downgrade | |
| Sep 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 03, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 28, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 28, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 27, 2023 | RBC Capital | Outperform | Outperform | Hold |
| Feb 03, 2023 | Piper Sandler | Overweight | Initialise | |
| Nov 17, 2022 | Goldman Sachs | Sell | Neutral | Upgrade |
| Jul 27, 2022 | SVB Leerink | Market Perform | Outperform | Upgrade |
| May 24, 2022 | Goldman Sachs | Sell | Sell | Hold |
| Feb 25, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Feb 22, 2022 | SVB Leerink | Market Perform | Market Perform | Hold |
Agios Pharmaceuticals's last stock rating was published by Raymond James on Oct 31, 2024. The company gave AGIO a "Outperform" rating, the same as its previous rate.
Agios Pharmaceuticals Financial Forecast
Agios Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $7.40M | $6.71M | $5.61M | $4.31M | $3.52M | $5.58M | $832.00K | - | - | - | - | $44.05M | $34.71M | $37.35M | $87.10M | $35.44M | $26.02M | $26.22M | $30.23M | $8.76M | $10.51M |
| Avg Forecast | $30.92M | $12.60M | $10.92M | $10.13M | $9.32M | $9.44M | $9.34M | $8.37M | $7.92M | $7.53M | $6.46M | $5.24M | $4.54M | $5.27M | $2.91M | $2.71M | $614.70K | $2.55M | $2.49M | $47.23M | $39.86M | $38.12M | $37.14M | $31.12M | $33.72M | $33.13M | $27.01M | $22.69M | $8.76M | $11.52M |
| High Forecast | $37.40M | $15.24M | $13.21M | $12.59M | $10.71M | $9.65M | $9.34M | $8.64M | $9.58M | $8.69M | $7.82M | $6.34M | $5.49M | $5.27M | $2.91M | $2.71M | $614.70K | $2.55M | $2.49M | $47.23M | $39.86M | $38.12M | $37.14M | $31.12M | $33.72M | $33.13M | $27.01M | $22.69M | $10.51M | $13.82M |
| Low Forecast | $25.81M | $10.52M | $9.12M | $8.46M | $8.28M | $9.22M | $9.34M | $8.10M | $6.61M | $6.91M | $5.39M | $4.38M | $3.79M | $5.27M | $2.91M | $2.71M | $614.70K | $2.55M | $2.49M | $47.23M | $39.86M | $38.12M | $37.14M | $31.12M | $33.72M | $33.13M | $27.01M | $22.69M | $7.01M | $9.21M |
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.98% | 1.04% | 1.07% | 0.95% | 0.67% | 1.92% | 0.31% | - | - | - | - | 1.11% | 0.91% | 1.01% | 2.80% | 1.05% | 0.79% | 0.97% | 1.33% | 1.00% | 0.91% |
Agios Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $7.92M, with a low forecast of $6.61M, and a high forecast of $9.58M. AGIO's average Quarter revenue forecast represents a 7.07% increase compared to the company's last Quarter revenue of $7.40M (Sep 23).
Agios Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-100.90M | $-93.70M | $-90.61M | $-225.21M | $-93.55M | $-98.05M | $-101.37M | $-92.09M | $-86.30M | $-83.96M | $1.88B | $-88.97M | $-86.81M | $-86.00M | $-34.85M | $-96.81M | $-101.20M | $-103.84M | $-86.67M | $-85.91M | $-63.69M |
| Avg Forecast | $-18.55M | $-7.56M | $-6.55M | $-6.08M | $-5.59M | $-5.66M | $-5.61M | $-83.18M | $-4.75M | $-4.52M | $-3.88M | $-88.96M | $294.38K | $-3.16M | $-1.74M | $-95.14M | $-368.82K | $-1.53M | $-1.49M | $-1.79B | $-23.92M | $-22.87M | $-22.28M | $-55.99M | $-20.23M | $-19.88M | $-16.20M | $-99.40M | $-89.10M | $-70.24M |
| High Forecast | $-15.49M | $-6.31M | $-5.47M | $-5.07M | $-4.97M | $-5.53M | $-5.61M | $-66.54M | $-3.97M | $-4.15M | $-3.24M | $-71.17M | $353.26K | $-3.16M | $-1.74M | $-76.12M | $-368.82K | $-1.53M | $-1.49M | $-1.43B | $-23.92M | $-22.87M | $-22.28M | $-44.80M | $-20.23M | $-19.88M | $-16.20M | $-79.52M | $-71.28M | $-56.19M |
| Low Forecast | $-22.44M | $-9.15M | $-7.93M | $-7.55M | $-6.43M | $-5.79M | $-5.61M | $-99.81M | $-5.75M | $-5.22M | $-4.69M | $-106.75M | $235.51K | $-3.16M | $-1.74M | $-114.17M | $-368.82K | $-1.53M | $-1.49M | $-2.15B | $-23.92M | $-22.87M | $-22.28M | $-67.19M | $-20.23M | $-19.88M | $-16.20M | $-119.28M | $-106.92M | $-84.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | 22.34% | 24.16% | 1.02% | -765.02% | 29.60% | 56.25% | 1.07% | 249.70% | 56.36% | 56.20% | -1.05% | 3.72% | 3.80% | 3.86% | 0.62% | 4.78% | 5.09% | 6.41% | 0.87% | 0.96% | 0.91% |
3 analysts predict AGIO's average Quarter EBITDA for Jun 21 to be $-1.49M, with a high of $-1.49M and a low of $-1.49M. This is -100.08% lower than Agios Pharmaceuticals's previous annual EBITDA (Mar 21) of $1.88B.
Agios Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | $-91.32M | $-83.81M | $-71.42M | $172.22M | $-72.40M | $-85.97M | $-88.40M | $-98.92M | $-88.77M | $-86.22M | $1.87B | $-97.66M | $-98.98M | $-90.48M | $-40.26M | $-102.35M | $-106.17M | $-109.87M | $-93.08M | $-90.83M | $-66.17M |
| Avg Forecast | $-80.41M | $-97.26M | $-98.27M | $-94.80M | $-98.33M | $889.10M | $-93.59M | $-86.06M | $-96.28M | $-99.48M | $-91.23M | $-92.04M | $-79.99M | $-100.22M | $-99.22M | $-98.44M | $-94.55M | $-89.01M | $-75.29M | $37.81B | $-74.25M | $-77.20M | $-77.46M | $-59.66M | $-96.35M | $-102.12M | $-96.55M | $-101.59M | $-90.83M | $-71.97M |
| High Forecast | $-63.13M | $-76.36M | $-77.15M | $-87.10M | $-88.61M | $1.13B | $-73.47M | $-68.85M | $-75.59M | $-81.20M | $-71.62M | $-73.63M | $-62.80M | $-100.22M | $-99.22M | $-78.75M | $-94.55M | $-89.01M | $-75.29M | $45.38B | $-74.25M | $-77.20M | $-77.46M | $-47.73M | $-96.35M | $-102.12M | $-96.55M | $-81.27M | $-72.66M | $-57.58M |
| Low Forecast | $-102.30M | $-123.74M | $-125.02M | $-100.13M | $-106.33M | $698.00M | $-119.07M | $-103.27M | $-122.50M | $-104.86M | $-116.06M | $-110.45M | $-101.76M | $-100.22M | $-99.22M | $-118.13M | $-94.55M | $-89.01M | $-75.29M | $30.25B | $-74.25M | $-77.20M | $-77.46M | $-71.59M | $-96.35M | $-102.12M | $-96.55M | $-121.91M | $-108.99M | $-86.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.92% | 0.92% | 0.78% | -2.15% | 0.72% | 0.87% | 0.90% | 1.05% | 1.00% | 1.15% | 0.05% | 1.32% | 1.28% | 1.17% | 0.67% | 1.06% | 1.04% | 1.14% | 0.92% | 1.00% | 0.92% |
Agios Pharmaceuticals's average Quarter net income forecast for Mar 23 is $-92.04M, with a range of $-110.45M to $-73.63M. AGIO's average Quarter net income forecast represents a -153.44% decrease compared to the company's last Quarter net income of $172.22M (Dec 22).
Agios Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | $25.82M | $30.41M | $28.37M | $32.77M | $29.12M | $28.26M | $31.52M | $31.53M | $27.15M | $29.21M | $33.55M | $39.78M | $34.84M | $35.95M | $38.50M | $34.83M | $33.02M | $32.39M | $31.79M | $24.55M | $14.82M |
| Avg Forecast | $98.13M | $40.00M | $34.67M | $32.14M | $29.58M | $29.95M | $29.65M | $26.56M | $25.14M | $23.88M | $20.51M | $16.64M | $-95.97K | $16.72M | $9.22M | $8.61M | $1.95M | $8.10M | $7.90M | $149.87M | $126.50M | $120.99M | $117.86M | $98.77M | $107.02M | $105.15M | $85.71M | $72.01M | $27.81M | $36.55M |
| High Forecast | $118.68M | $48.37M | $41.93M | $39.96M | $33.99M | $30.64M | $29.65M | $27.41M | $30.41M | $27.59M | $24.80M | $20.12M | $-76.78K | $16.72M | $9.22M | $8.61M | $1.95M | $8.10M | $7.90M | $149.87M | $126.50M | $120.99M | $117.86M | $98.77M | $107.02M | $105.15M | $85.71M | $72.01M | $33.37M | $43.87M |
| Low Forecast | $81.91M | $33.39M | $28.94M | $26.84M | $26.29M | $29.26M | $29.65M | $25.71M | $20.98M | $21.94M | $17.12M | $13.89M | $-115.17K | $16.72M | $9.22M | $8.61M | $1.95M | $8.10M | $7.90M | $149.87M | $126.50M | $120.99M | $117.86M | $98.77M | $107.02M | $105.15M | $85.71M | $72.01M | $22.25M | $29.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.08% | 1.48% | 1.70% | -341.46% | 1.74% | 3.07% | 3.66% | 16.16% | 3.35% | 3.70% | 0.22% | 0.31% | 0.29% | 0.31% | 0.39% | 0.33% | 0.31% | 0.38% | 0.44% | 0.88% | 0.41% |
Agios Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $25.14M, based on 3 Wall Street analysts, with a range of $20.98M to $30.41M. The forecast indicates a -2.64% fall compared to AGIO last annual SG&A of $25.82M (Sep 23).
Agios Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.64 | $-1.51 | $-1.29 | $3.14 | $-1.32 | $-1.57 | $-1.62 | $-1.82 | $-1.56 | $-1.41 | $26.95 | $-1.41 | $-1.43 | $-1.31 | $-0.59 | $-1.60 | $-1.81 | $-1.87 | $-1.59 | $-1.63 | $-1.56 |
| Avg Forecast | $-1.38 | $-1.66 | $-1.68 | $-1.62 | $-1.68 | $15.22 | $-1.60 | $-1.65 | $-1.65 | $-1.70 | $-1.56 | $-1.70 | $-1.37 | $-1.76 | $-1.75 | $-1.74 | $-1.66 | $-1.57 | $-1.33 | $-1.29 | $-1.31 | $-1.36 | $-1.36 | $-1.67 | $-1.70 | $-1.80 | $-1.70 | $-1.75 | $-1.63 | $-1.86 |
| High Forecast | $-1.08 | $-1.31 | $-1.32 | $-1.49 | $-1.52 | $19.36 | $-1.26 | $-1.29 | $-1.29 | $-1.39 | $-1.23 | $-1.34 | $-1.07 | $-1.76 | $-1.75 | $-1.74 | $-1.66 | $-1.57 | $-1.33 | $-1.29 | $-1.31 | $-1.36 | $-1.36 | $-1.67 | $-1.70 | $-1.80 | $-1.70 | $-1.75 | $-1.30 | $-1.49 |
| Low Forecast | $-1.75 | $-2.12 | $-2.14 | $-1.71 | $-1.82 | $11.95 | $-2.04 | $-2.10 | $-2.10 | $-1.79 | $-1.99 | $-2.16 | $-1.74 | $-1.76 | $-1.75 | $-1.74 | $-1.66 | $-1.57 | $-1.33 | $-1.29 | $-1.31 | $-1.36 | $-1.36 | $-1.67 | $-1.70 | $-1.80 | $-1.70 | $-1.75 | $-1.96 | $-2.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.96% | 0.97% | 0.76% | -2.29% | 0.75% | 0.90% | 0.93% | 1.09% | 1.00% | 1.06% | -20.85% | 1.08% | 1.05% | 0.96% | 0.35% | 0.94% | 1.01% | 1.10% | 0.91% | 1.00% | 0.84% |
According to 3 Wall Street analysts, Agios Pharmaceuticals's projected average Quarter EPS for Mar 23 is $-1.70, with a low estimate of $-2.16 and a high estimate of $-1.34. This represents a -154.18% decrease compared to AGIO previous annual EPS of $3.14 (Dec 22).
Agios Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| KROS | Keros Therapeutics | $18.00 | $102.00 | 466.67% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| ANAB | AnaptysBio | $15.99 | $49.83 | 211.63% | Buy |
| ARVN | Arvinas | $19.10 | $58.50 | 206.28% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| KALV | KalVista Pharmaceuticals | $8.65 | $22.67 | 162.08% | Buy |
| PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| SNDX | Syndax Pharmaceuticals | $13.63 | $31.67 | 132.36% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| IDYA | IDEAYA Biosciences | $26.33 | $53.33 | 102.54% | Buy |
| COGT | Cogent Biosciences | $8.19 | $16.00 | 95.36% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| NRIX | Nurix Therapeutics | $21.18 | $32.67 | 54.25% | Buy |
| MRSN | Mersana Therapeutics | $2.03 | $3.00 | 47.78% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| MGTX | MeiraGTx | $6.40 | $9.00 | 40.63% | Buy |
| BMRN | BioMarin Pharmaceutical | $67.19 | $94.43 | 40.54% | Buy |
| KYMR | Kymera Therapeutics | $42.30 | $58.60 | 38.53% | Buy |
| AGIO | Agios Pharmaceuticals | $41.96 | $53.50 | 27.50% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |